XML 273 R216.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segment information - Schedule of Segment Results (Details) - EUR (€) € in Millions | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Disclosure of operating segments [line items] |  |  |  |  |
Net sales | € 41,081 | € 37,817 | [1] | € 37,651 | [1]
Other revenues | 3,205 | 3,801 | [1],[2] | 2,910 | [1],[2]
Cost of sales | (13,205) | (12,628) | [1] | (11,882) | [1]
Research and development expenses | (7,394) | (6,507) | [1] | (6,501) | [1]
Selling and general expenses | (9,183) | (8,933) | [1] | (8,739) | [1]
Net income attributable to non-controlling interests | 58 | 36 | [1],[3] | 113 | [1],[3]
Biopharma (operating segment) |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) | 415 |  |  |  |
Biopharma (operating segment) | Research and development projects and technology platforms |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) | 640 |  |  |  |
Total |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |
Net sales | 41,081 | 37,817 | [4] | 37,651 | [5],[6]
Other revenues | 3,205 | 3,801 | [4] | 2,910 | [5],[6]
Cost of sales | (13,195) | (12,619) | [4] | (11,879) | [5],[6]
Research and development expenses | (7,394) | (6,507) | [4] | (6,501) | [5],[6]
Selling and general expenses | (9,183) | (8,933) | [4] | (8,739) | [5],[6]
Other operating income and expenses | (3,293) | (2,464) | [4] | (709) | [5],[6]
Share of profit/(loss) from investments accounted for using the equity method | 136 | 101 | [4] | 76 | [5],[6]
Net income attributable to non-controlling interests | (14) | (18) | [4] | (16) | [5],[6]
Business operating income | 11,343 | 11,178 | [4] | 12,793 | [5],[6]
Biopharma (operating segment) |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |
Net sales | 41,081 | 37,817 | [4],[7] | 37,651 | [5],[6],[7]
Other revenues | 2,866 | 3,505 | [2],[4] | 2,534 | [2],[5],[6]
Cost of sales | (12,973) | (12,415) | [4] | (11,682) | [5],[6]
Research and development expenses | (7,393) | (6,505) | [4] | (6,499) | [5],[6]
Selling and general expenses | (9,113) | (8,854) | [4] | (8,536) | [5],[6]
Other operating income and expenses | (3,305) | (2,476) | [4] | (764) | [5],[6]
Share of profit/(loss) from investments accounted for using the equity method | 136 | 101 | [4] | 76 | [5],[6]
Net income attributable to non-controlling interests | (14) | (18) | [4] | (16) | [5],[6]
Business operating income | 11,285 | 11,155 | [4] | 12,764 | [5],[6]
Other |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |
Net sales | 0 | 0 | [4] | 0 | [5],[6]
Other revenues | 339 | 296 | [4] | 376 | [5],[6]
Cost of sales | (222) | (204) | [4] | (197) | [5],[6]
Research and development expenses | (1) | (2) | [4] | (2) | [5],[6]
Selling and general expenses | (70) | (79) | [4] | (203) | [5],[6]
Other operating income and expenses | 12 | 12 | [4] | 55 | [5],[6]
Share of profit/(loss) from investments accounted for using the equity method | 0 | 0 | [4] | 0 | [5],[6]
Net income attributable to non-controlling interests | 0 | 0 | [4] | 0 | [5],[6]
Business operating income | € 58 | € 23 | [4] | € 29 | [5],[6]
[1] | Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] | (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3] | Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations).
[4] | Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[5] | (a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[6] | (b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€706 million net of tax).
[7] | (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

X
- Definition The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 99 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_CostOfSales
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_OtherRevenue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2023-01-01 -Paragraph 12 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_e&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 81B -Subparagraph a -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_i&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ProfitLossAttributableToNoncontrollingInterests
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of expenditure directly attributable to research or development activities, recognised in profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 126 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ResearchAndDevelopmentExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of revenue arising from the sale of goods. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_RevenueFromSaleOfGoods
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of expense relating to selling, general and administrative activities of the entity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 85 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_SellingGeneralAndAdministrativeExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 28 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 23 -Subparagraph g -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_g&doctype=Standard -URIDate 2023-03-23 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 82 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business operating income. + References No definition available. + Details
Name: | sny_BusinessOperatingIncome
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Impairment loss on intangible assets other than goodwill. + References No definition available. + Details
Name: | sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Other operating income and expenses. + References No definition available. + Details
Name: | sny_MiscellaneousOtherOperatingIncomeExpenses
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=sny_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=ifrs-full_ReportableSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=ifrs-full_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |